Zentalis Q3: azenosertib 37% ORR, $517M cash, NDA on track for 2026

Zentalis Pharmaceuticals, Inc.

2023-Q3 EPS reported -$3.64

Azenosertib monotherapy achieved 37% ORR and 6.5-month mPFS in heavily pretreated ovarian/uterine serous carcinoma.
Cash, equivalents & marketable securities of $516.6M as of Sept 30, 2023; projected runway into 2026.
First NDA for azenosertib targeted in 2026 for a gynecologic malignancy; numerous trials ongoing.
Mark Lackner, Ph.D., to succeed co-founder Kevin Bunker, Ph.D., as Chief Scientific Officer at year-end.
ZN-d5 development in AL amyloidosis discontinued to focus resources on azenosertib franchise.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Zentalis Pharmaceuticals, Inc. reported financial results for quarter ended September 30, 2023.

Period: quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 6, 2023, Zentalis Pharmaceuticals, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2023 and commented on certain business updates.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Zentalis Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001725160-23-000195

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.